WST West Pharmaceutical Services Inc

$276.93

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending
Expected on
Report Time: Unknown Release Time
The Whisper Number
Consensus Estimate:
Revenue Estimate:

Latest Earnings Insight

West Pharmaceutical Services (WST) is poised for its upcoming earnings report on October 23, with the market closely eyeing its ability to navigate the evolving healthcare landscape. The company, with a market cap of approximately $18.8 billion, has been a key player in the pharmaceutical packaging and delivery systems sector, a field that has seen consistent demand due to ongoing global health initiatives. Analysts have set an EPS estimate of $1.69, while the whisper number suggests a more optimistic $1.93, indicating higher expectations from some market participants. Revenue is projected at $786.33 million, reflecting the company's strategic focus on expanding its product offerings and enhancing operational efficiencies. As investors await the results, the whisper number serves as a benchmark for potential outperformance, highlighting the market's confidence in West Pharmaceutical's ability to deliver robust financial results amidst a competitive environment.

Updated On 1/6/2026

About West Pharmaceutical Services Inc

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Website: https://www.westpharma.com

Sector
MANUFACTURING
Industry
FABRICATED RUBBER PRODUCTS, NEC
Exchange
NYSE
Country
USA
Currency
USD
Fiscal Year End
December
CIK
105770
Address
530 HERMAN O. WEST DRIVE, EXTON, PA, US
Valuation
Market Cap
$14.60B
P/E Ratio
30.22
PEG Ratio
3.38
Price to Book
5.44
Performance
EPS
$6.68
Dividend Yield
0.42%
Profit Margin
17.00%
ROE
17.70%
Technicals
50D MA
$229.60
200D MA
$293.32
52W High
$393.65
52W Low
$187.43
Fundamentals
Shares Outstanding
72M
Target Price
$284.51
Beta
1.22

WST EPS Estimates vs Actual

Estimated
Actual

WST News & Sentiment

Dec 29, 2025 • MarketBeat BULLISH
West Pharmaceutical Services, Inc. $WST Shares Acquired by Annex Advisory Services LLC
Annex Advisory Services LLC has increased its stake in West Pharmaceutical Services Inc. (NYSE: WST) by 63.7%, now owning 113,158 shares valued at approximately $29.7 million. The company recently reported strong quarterly earnings, beating expectations with an EPS of $1.96 and revenues of $804.6 million, and also declared a quarterly dividend of $0.22 per share. Institutional ownership of West Pharmaceutical Services stands at 93.90%, and analysts have a "Moderate Buy" consensus rating with a target price of $342.20.
Dec 26, 2025 • MarketBeat SOMEWHAT-BULLISH
Swedbank AB Grows Stock Position in IES Holdings, Inc. $IESC
Swedbank AB significantly increased its stake in IES Holdings, Inc. (NASDAQ:IESC) by 153.1% in Q3, now owning 81,000 shares valued at $32.21 million. This comes as company insiders have sold shares totaling about $96.39 million, while institutional investors now own 86.60% of the stock. Analysts have a positive outlook, with Wall Street Zen upgrading IES to a "strong-buy" rating.
Dec 24, 2025 • MSN BULLISH
Reasons to retain West Pharmaceutical stock in your portfolio for now
This article from MSN provides reasons to retain West Pharmaceutical stock. Despite not having direct content, the title suggests a positive outlook on the company's shares. Investors could infer that factors support holding onto this stock in their portfolios.
Dec 23, 2025 • MyChesCo SOMEWHAT-BULLISH
Annovis Sets Investor Webinar as Neurodegeneration Pipeline Reaches Inflection
Annovis Bio, Inc. (NYSE: ANVS) announced it will host an investor webinar on Wednesday, January 28, 2026, at 4:30 p.m. Eastern, to provide a corporate update as its neurodegeneration pipeline enters a "milestone-rich period." The webinar will feature President and CEO Maria Maccecchini discussing company progress, clinical study updates, and strategic direction, followed by a live Q&A session. The company focuses on developing therapies for Alzheimer's and Parkinson's diseases, aiming to slow or halt neurodegeneration.
Dec 23, 2025 • FinancialContent BULLISH
The Biotech Revolution’s Ultimate ‘Picks and Shovels’ Play: A Deep Dive into West Pharmaceutical Services (WST)
West Pharmaceutical Services (WST) is highlighted as a critical "picks and shovels" provider for the booming biotech industry, supplying essential drug delivery components. After facing initial skepticism in early 2025 due to inventory destocking, WST demonstrated a strong turnaround in the second half of the year, driven by increased demand for its high-value products and bolstered by regulatory tailwinds like EU GMP Annex 1. The company is poised for further growth with the upcoming launch of its Synchrony™ PFS System and potential M&A in smart delivery technologies, positioning it as an indispensable partner in the high-stakes world of modern medicine.
Dec 23, 2025 • FinancialContent BULLISH
The Biotech Revolution’s Ultimate ‘Picks and Shovels’ Play: A Deep Dive into West Pharmaceutical Services (WST)
West Pharmaceutical Services (WST) has become a critical "picks and shovels" provider for the pharmaceutical industry, supplying specialized delivery systems for new drugs like GLP-1 therapies and biologics. After a period of "inventory destocking" in 2024, WST has shown strong recovery in 2025, driven by high-value product demand and regulatory shifts like EU GMP Annex 1. The company is positioned for continued growth with new product launches and potential M&A in digital health, making it an essential infrastructure play in the biotech revolution.
Sentiment Snapshot

Average Sentiment Score:

0.291
50 articles with scored sentiment

Overall Sentiment:

Bullish

WST Reported Earnings

Jul 24, 2025
Jun 30, 2025 (Pre market)
0.33 Surprise
  • Reported EPS: $1.84
  • Estimate: $1.51
  • Whisper:
  • Surprise %: 21.9%
Apr 24, 2025
Mar 31, 2025 (Pre market)
0.19 Surprise
  • Reported EPS: $1.45
  • Estimate: $1.26
  • Whisper:
  • Surprise %: 15.3%
Feb 13, 2025
Dec 31, 2024 (Pre market)
0.11 Surprise
  • Reported EPS: $1.82
  • Estimate: $1.71
  • Whisper:
  • Surprise %: 6.4%
Oct 24, 2024
Sep 30, 2024 (Pre market)
0.35 Surprise
  • Reported EPS: $1.85
  • Estimate: $1.50
  • Whisper:
  • Surprise %: 23.3%
Jul 25, 2024
Jun 30, 2024 (Pre market)
-0.22 Surprise
  • Reported EPS: $1.52
  • Estimate: $1.74
  • Whisper:
  • Surprise %: -12.6%
Apr 25, 2024
Mar 31, 2024 (Pre market)
0.3 Surprise
  • Reported EPS: $1.56
  • Estimate: $1.26
  • Whisper:
  • Surprise %: 23.8%
Feb 15, 2024
Dec 31, 2023 (Pre market)
0.05 Surprise
  • Reported EPS: $1.83
  • Estimate: $1.78
  • Whisper:
  • Surprise %: 2.8%
Oct 26, 2023
Sep 30, 2023 (Pre market)
0.3 Surprise
  • Reported EPS: $2.16
  • Estimate: $1.86
  • Whisper:
  • Surprise %: 16.1%
Jul 27, 2023
Jun 30, 2023 (Pre market)
0.18 Surprise
  • Reported EPS: $2.11
  • Estimate: $1.93
  • Whisper:
  • Surprise %: 9.3%

Financials